NASDAQ · IBRX
Healthcare · Biotechnology
$8.14
Down-$0.23 (-2.83%)
Updated Sep 17, 2026, 12:03 AM
SID Score
6.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 19 trading sessions · Daily adjusted prices
IBRX closed at $8.14 after 19 trading sessions, up 0.12% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $8.32 | $8.34 | $7.85 | $8.14 | 8.95M |
| Sep 14, 2026 | $7.89 | $8.40 | $7.87 | $8.37 | 9.16M |
| Sep 11, 2026 | $7.80 | $8.345 | $7.80 | $7.91 | 12.47M |
| Sep 10, 2026 | $7.87 | $7.89 | $7.64 | $7.72 | 8.81M |
| Sep 9, 2026 | $8.22 | $8.36 | $7.875 | $8.06 | 9.49M |
| Sep 8, 2026 | $8.00 | $8.37 | $7.93 | $8.29 | 7.74M |
| Sep 4, 2026 | $8.08 | $8.24 | $8.01 | $8.08 | 4.33M |
| Sep 3, 2026 | $8.00 | $8.21 | $7.88 | $8.19 | 5.27M |
| Sep 2, 2026 | $7.945 | $8.28 | $7.755 | $7.95 | 7.23M |
| Sep 1, 2026 | $7.82 | $7.99 | $7.73 | $7.87 | 6.47M |
| Aug 31, 2026 | $7.88 | $8.0195 | $7.84 | $7.95 | 6.88M |
| Aug 28, 2026 | $8.31 | $8.3199 | $7.945 | $8.05 | 7.98M |
| Aug 27, 2026 | $8.24 | $8.76 | $8.18 | $8.40 | 12.31M |
| Aug 26, 2026 | $8.17 | $8.40 | $8.07 | $8.25 | 9.45M |
| Aug 25, 2026 | $7.69 | $8.23 | $7.68 | $8.19 | 11.55M |
| Aug 24, 2026 | $7.68 | $7.72 | $7.46 | $7.58 | 5.67M |
| Aug 21, 2026 | $7.85 | $7.95 | $7.60 | $7.79 | 7.62M |
| Aug 20, 2026 | $7.90 | $8.00 | $7.74 | $7.84 | 8.1M |
| Aug 19, 2026 | $8.08 | $8.27 | $7.94 | $8.13 | 13.06M |
The latest Smart Investors Daily articles mentioning IBRX.
IBRX research
Company profile and research snapshot.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 2, 2026 | HC Wainwright & Co. | Buy | — |
| May 21, 2026 | BTIG | Buy | — |
| May 20, 2026 | HC Wainwright & Co. | Buy | — |
| May 5, 2026 | D. Boral Capital | Buy | — |
| Apr 21, 2026 | D. Boral Capital | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 14, 2026
PDS Biotech said it completed the initial close of a Nant Capital-led PIPE of up to $22.3 million and seated Soon-Shiong on its board — tying IBRX’s public face to a second immunotherapy platform.
Yahoo · Sep 14, 2026
Gross Proceeds of $11.3 Million at Initial Closing Transaction Led by Dr. Patrick Soon-Shiong, Founder of NantWorks PRINCETON, N.J., Sept. 14, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer, today announced the initial closing (the “Initial Closing”) of the Company’s Private Investment in Public Equity (“PIPE”) transaction. The round was led by
Yahoo · Sep 14, 2026
ImmunityBio is attending major conferences in Seoul and New York, followed by several oncology events through November.
Yahoo · Sep 11, 2026
A new patent application covers using Anktiva to restore immune cells depleted by cancer treatments.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning IBRX.
